RUXOLINIB FOR MYELOFIBROSIS
-
Upload
seayat1103 -
Category
Health & Medicine
-
view
1.361 -
download
2
Transcript of RUXOLINIB FOR MYELOFIBROSIS
![Page 1: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/1.jpg)
VS洪英中 /R4洪逸平
RUXOLINIB FOR MYELOFIBROSIS
N Engl J Med 2012;366:799-807
N Engl J Med 2012;366:787-98.
![Page 2: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/2.jpg)
Myelofibrosis• Epidemiology• Mainly in middle aged and elder patients, the median age at
presentation is 67 y/o
• Clinical Manifestation• Constitutional symptoms• Weight loss 10% of baseline in the year
• Unexplained fever
• Excessive sweats persisting for 1 month
• Splenomegaly• Hepatomegaly• Extramedullary hematopoiesis• Thrombotic events• Bone and joint involvement
![Page 3: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/3.jpg)
Cause of Bone Marrow Fibrosis
![Page 4: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/4.jpg)
Primary Myelofibrosis•Major Criteria• Atypical megakaryocytic hyperplasia, often accompanied by
reticulin and/or collagen fibrosis or in the absence of fibrosis, megakaryocytic atypia and marrow hypercellularity with myeloid hyperplasia and erythroid hypoplasia • Exclusion of WHO criteria for PV, CML, MDS, or other MPDs • JAK2V617F mutation or other clonal marker or if no clonal
marker, exclusion of marrow fibrosis secondary to inflammatory or other neoplastic disorders
•Minor Criteria• Leukoerythroblastosis • Elevated serum lactate dehydrogenase level • Anemia • Palpable splenomegaly
![Page 5: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/5.jpg)
Pathogenesis of myelofibrosis
![Page 6: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/6.jpg)
Somatic mutations in classic MPD including primary myelofibrosis, PV and ET
![Page 7: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/7.jpg)
Somatic mutations in classic MPD including primary myelofibrosis, PV and ET
![Page 8: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/8.jpg)
The Dynamic International Prognostic Scoring System (DIPSS)
The Dynamic International Prognostic Scoring System (DIPSS)
• Weight loss 10% of baseline in the year
• Unexplained fever• Excessive sweats persisting for
1 month
BLOOD, 31 MARCH 2011 VOLUME 117, NUMBER
• complex karyotype • 1 or 2 abnormalities that
include +8, 7/7q, i(17q), inv(3), 5/5q 12p, or 11q23 rearrangement
![Page 9: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/9.jpg)
Prognosis based on DIPSSOverall Survival Leukemia-free survival
185783516
J Clin Oncol 29:392-397
![Page 10: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/10.jpg)
Treatment Option•Low- or intermediate 1–risk disease• Asymptomatic: Watch and Wait• Symptomatic: Conventional drug therapy is indicated
• Intermediate 2– or high-risk disease• Conventional drug therapy • Splenectomy• Radiotherapy
• Allo-SCT• Experimental drug therapy
![Page 11: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/11.jpg)
Drug Response Rate
Duration
Effect Adverse Effect
Special consideration
Erythropoiesis-stimulation Factor (DPO)
< 56% 1 year Drug-induced exacerbation of splenomegaly
Symptomatic anemia, not transfusion dependent, serum EPO<125
Corticosteroid(0.5mg/kg/d)
20% 1 year
Androgen(fluoxymesterone 10mg tid)
20% 1 year hepatotoxicity and virilizing effects
Danazole(600mg/d)
20% 1 year
Thalidomide(50mg/d)
20% 1 year Anemia, thrombocytopenia, and splenomegaly
Peripheral neuropathy
May add with steroid
Lenalidomide(10mg/d)
20% 1 year Response in Anemia and splenomegaly
neutropenia or thrombocytopenia
Favored in Del(5q)May add aspirin
Hydroxyurea
35% 1 year Splenomegaly Myelosuppresion, xeroderma, mucocutaneous ulcers
Response lower in JAK2V617F(-)
![Page 12: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/12.jpg)
Splenectomy• Indication:• drug-refractory symptomatic splenomegaly• severe discomfort or pain, • frequent red blood cell transfusions, • severe thrombocytopenia,• symptomatic portal hypertension, • profound cachexia
• Response rate: >50%• Duration: 1 year• Perioperative mortality rate: 5-10%, Morbidity rate: 25%• Leukemia transformation: Indeterminate
![Page 13: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/13.jpg)
Radiotherapy• Indication: • non–hepatosplenic EMH,• vertebral column (spinal cord compression),
• lymph nodes (lymphadenopathy),
• pleura (pleural effusion),
• peritoneum (ascites),
• skin(cutaneous nodules)
low-dose radiotherapy (100-500 cGy in 5-10 fractions).
• pulmonary hypertensionsingle-fraction (100 cGy) whole-lung irradiation
• lower or upper extremity painSingle fraction of 100-400 cGy
![Page 14: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/14.jpg)
Allogeneic stem cell transplantation• The only treatment option in MF that is capable of inducing complete hematologic, cytogenetic, and molecular remissions.Study Case
Duprez score
Regimen 3-y OS
Recurrence rate
Non-relapse mortality rate
Extensive GVHD
Stewart WA et al in UK
51 pts,low:24%, intermediate:33%, High:43%
CIC(conventional-intensity)
44% 15% 41% 30%
RIC(reduced intensity)
31% 46% 32% 35%
![Page 15: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/15.jpg)
Allogeneic stem cell transplantation
Study CaseDuprez score
Treatment related mortality
5-y OS 3-year DFS
Ballen KK et al, USA
289 pts,Low:32%Intermediate: 36%High: 31%
1 year:27%5 year:35%
37% 39%
1 year:43%5 year:50%(unrelated donor)
30% 17%
Francesca Patriarca et al, Italy
100 ptsLow:10%Int.:58%High:32%
1 year:35%3 year:43%
31% 35%
![Page 16: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/16.jpg)
Myelofibrosis Treatment Algorithm
BLOOD, 31 MARCH 2011 VOLUME 117, NUMBER 13
![Page 17: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/17.jpg)
JAK inhibitors in Clinical Trial
![Page 18: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/18.jpg)
![Page 19: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/19.jpg)
Putative Mechanisms of Disease and Drug Action of JAK Inhibitors in Myelofibrosis
![Page 20: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/20.jpg)
Ruxolitinib (INCB018424)•Potent inhibitor of JAK1 and JAK2•Had durable reduction in splenomegaly and improve myelofibrosis related symptom•Related Trial:• the Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment I(COMFORT-I)• the Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment II (COMFORT-II)
![Page 21: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/21.jpg)
Compare the current 2 trial in NEJMCOMFORT-I (n=309) COMFORT-II (n=219)
Initiater Srdan Verstovsek et al in the US
Claire Harrison et al in the UK
Inclusion criteria
>18y/oPrimary myelofibrosisPost-PV MFPost-ET MFIPSS ≧ 3 (int. 2 and high risk)ECOG ≦ 3Peripheral blast < 10%plt > 100kpalpable splenomegaly(≥5 cm below the left costal margin)
>18y/oPrimary myelofibrosisPost-PV MFPost-ET MFIPSS ≧ 3 (int. 2 and high risk)ECOG ≦ 3Peripheral blast < 10%plt > 100kpalpable splenomegaly(≥5 cm below the left costal margin)
Study design Double blindRandomly assigned, 1:1 ratioRuxotinib/placeboCrossover to Ruxotinib was permitted if splenomegaly worsening
Randomly assigned, 2:1 ratioRuxolitinib/ Best available therapyThe best available treatment group may shift to Ruxotinib group if spleen volume > 25%
Drop out criteria
Leukemic transformation or splenic irradiation
Primary End Point
reduction of 35% or more in spleen volume
reduction of 35% or more in spleen volume
![Page 22: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/22.jpg)
ResultCOMFORT-I(n=309) COMFORT-II (n=219)
Spleen Size (reduction>35%)
Ruxolitinib: 41.9% at week 24
32% at week 24, 28% at week 48
Placebo: 0.7% at week 24 0% at week 24, 0% at week 48
Biomarkers Ruxolitinib
JAK2V617F allele burden-10.9% at week 24 -21.5% at week 48Reduction in CRP, TNF-alpha, IL-6Increase in leptin, erythropoietin
Reduction in CRP, IL-6, TNF-alphaIncrease in leptin, erythropoietin
Placebo JAK2V617F allele burden3.5% at week 24 6.3% at week 48
Overall Survival
At median F/u 51 weeks13 deaths in Ruxolitinib(8.4%)24 deaths in placebo(15.6%)Hazard ratio: 0.50, p=0.04
At 12 months f/u6 deaths in Ruxoliinib (4%)4 deaths in best.. Group (5%)Hazard ratio: 0.7 (95% CI 0.20-2.49)
![Page 23: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/23.jpg)
Spleen Size COMFORT-I COMFORT-II
![Page 24: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/24.jpg)
COMFORT-I COMFORT-II
![Page 25: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/25.jpg)
Overall Survival
• At 12 months f/u• 6 deaths in
Ruxoliinib (4%)• 4 deaths in best..
Group (5%)• Hazard ratio: 0.7
(95% CI 0.20-2.49)
No survival benefit!
COMFORT-I COMFORT-II
![Page 26: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/26.jpg)
Side Effect
![Page 27: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/27.jpg)
Discussion• Ruxolitinib resulted in a rapid reduction of splenomegaly, which was observed at week 8 and continued through week 48• Ruxolitinib also resulted in change of cytokine levels• Ruxolitinib was associated with increased frequencies of anemia and thrombocytopenia• Response rate was higher in JAK2 V617F positive group (33%:14%)• The minimal benefit to survival in COMFORT-II may be due to 25% patient in the best available treatment group crossover to Ruxolitinib group and 12% withdrawn consent. However, OS benefit is noted in COMFORT-I
![Page 28: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/28.jpg)
Take Home Message• Myelofibrosis is a disease of bone marrow fibrosis, manifested as splenomegaly, fatigue, extramedullary hematopoiesis, and thrombotic events• Treatment includes: • Conventional drugs,• Splenectomy• Radiotherapy • Allo-SCT • New drugs
• Ruxolitinib is a JAK1 and JAK2 inhibitor• Ruxolitinib is effective on reduction of spleen size, improve the symptoms and quality of life, however OS indeterminate
![Page 29: RUXOLINIB FOR MYELOFIBROSIS](https://reader037.fdocuments.net/reader037/viewer/2022103113/554b44ebb4c905cd2c8b4fae/html5/thumbnails/29.jpg)
Thanks for Your Attention!!